BioCatalyst

PCVX — Vaxcyte, Inc. catalysts

2 verified catalyst event(s) for Vaxcyte, Inc. (ticker PCVX). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2027-03-01 — A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With I · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX
Phase 3 · Pneumococcal Disease
 PCVX Vaxcyte, Inc. 31-valent pneumococcal conjugate vaccine ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2027-03 (month)
in 4mo
ESTIMATED
 READOUT
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prio
Phase 3 · Pneumococcal Vaccines
 PCVX Vaxcyte, Inc. 31-valent pneumococcal conjugate vaccine ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.